{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T17:42:54Z","timestamp":1775929374285,"version":"3.50.1"},"reference-count":0,"publisher":"OAE Publishing Inc.","content-domain":{"domain":["oaepublish.com"],"crossmark-restriction":false},"short-container-title":["CDR"],"DOI":"10.20517\/cdr.2021.55","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T12:24:19Z","timestamp":1629980659000},"update-policy":"https:\/\/doi.org\/10.20517\/oae.crossmark.policy","source":"Crossref","is-referenced-by-count":9,"title":["MYC inhibitors in multiple myeloma"],"prefix":"10.20517","author":[{"given":"Sandra","family":"Mart\u00ednez-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Soucek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8410","published-online":{"date-parts":[[2021]]},"container-title":["Cancer Drug Resistance"],"original-title":[],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T08:45:42Z","timestamp":1705567542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oaepublish.com\/articles\/cdr.2021.55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":0,"URL":"https:\/\/doi.org\/10.20517\/cdr.2021.55","relation":{},"subject":[],"published":{"date-parts":[[2021]]}}}